Published :
Tables : 45
Figures : 43
Category : Healthcare
No. of Pages : 211
Report Code : HC-1127
Triple Negative Breast Cancer Treatment Market Introduction Triple-Negative Breast Cancer Treatment Market is forecasted to value over US$ 820 million by 2027 end and register a CAGR of over 4.5% from 2020 to 2027. Triple-negative breast cancer is a type of cancer that does not have any receptors for hormones progesterone and estrogen. Triple-negative breast cancer does not respond to hormonal therapy and requires combines surgery. Based on drug type the market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin/carboplatin, and others. Doxorubicin is a chemotherapy drug used to treat acute lymphocytic leukemia, breast cancer, and bladder cancer. It slows down the growth of the cancer cells. Paclitaxel injection is used in the treatment of stomach cancer, prostate cancer, testicular cancer, and breast cancer. Doxorubicin can also interact with cyclophosphamide and paclitaxel. Based on the distribution channel, the market is bifurcated into hospital pharmacies and speciality cancer clinics. Speciality cancer clinics are the biggest end users owing to the easy availability of facilities. The growing need for effective treatment against breast cancer is driving the growth of the market. A gradual increase in research and development alongside the adoption of new treatment types against cancer is expected to spur the size of the market. Collaborations among prominent players in development and research of innovative and new drug are stimulating the size of the market. In addition, the robust pipeline of drugs in clinical development to diagnose triple-negative breast cancer treatment is also fueling the growth of the market. A huge trend spotted in the triple-negative breast cancer treatment is the evolution of nanotechnology. Nanotechnology has emerged as an efficient tool in the clinical management of triple-negative breast cancer. North America currently holds a vast share of the market. The presence of prominent players alongside advanced healthcare infrastructure has expanded the size of the market. The Asia Pacific and Latin America regions have established vast potential opportunistic space for manufacturers thanks to an increase in treatment rate and rising prevalence of triple-negative breast. Increasing healthcare infrastructure in countries like India and China is expected to boost the growth of the market in the region in the coming years. Established players of the market are: AstraZeneca PLC, Pfizer, Inc. , F. Hoffman - La Roche Ltd. , Bristol-Myers Squibb Company, Novartis AG, Mylan N.V. , Eli Lilly and Company, Celgene Corporation, Sanofi S.A., and Johnson & Johnson Services, Inc., among others. Triple-Negative Breast Cancer Treatment Market Segmentation: By Drug Type • Doxorubicin • Cyclophosphamide • Paclitaxel • Docetaxel • Cisplatin/Carboplatin • Others By Distribution Channel • Hospital Pharmacies • Specialty Cancer Clinics By Region • Europe • North America • APAC • Latin America • Rest of World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on Global Triple-Negative Breast Cancer Treatment Market by Drug Type, by Distribution Channel, by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Triple-Negative Breast Cancer Treatment Market is forecasted to value over US$ 820 million by 2027 end and register a CAGR of over 4.5% from 2020 to 2027.
Triple-negative breast cancer is a type of cancer that does not have any receptors for hormones progesterone and estrogen. Triple-negative breast cancer does not respond to hormonal therapy and requires combines surgery.
Based on drug type the market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin/carboplatin, and others. Doxorubicin is a chemotherapy drug used to treat acute lymphocytic leukemia, breast cancer, and bladder cancer. It slows down the growth of the cancer cells. Paclitaxel injection is used in the treatment of stomach cancer, prostate cancer, testicular cancer, and breast cancer. Doxorubicin can also interact with cyclophosphamide and paclitaxel. Based on the distribution channel, the market is bifurcated into hospital pharmacies and speciality cancer clinics. Speciality cancer clinics are the biggest end users owing to the easy availability of facilities.
The growing need for effective treatment against breast cancer is driving the growth of the market. A gradual increase in research and development alongside the adoption of new treatment types against cancer is expected to spur the size of the market.
Collaborations among prominent players in development and research of innovative and new drug are stimulating the size of the market. In addition, the robust pipeline of drugs in clinical development to diagnose triple-negative breast cancer treatment is also fueling the growth of the market. A huge trend spotted in the triple-negative breast cancer treatment is the evolution of nanotechnology. Nanotechnology has emerged as an efficient tool in the clinical management of triple-negative breast cancer.
North America currently holds a vast share of the market. The presence of prominent players alongside advanced healthcare infrastructure has expanded the size of the market. The Asia Pacific and Latin America regions have established vast potential opportunistic space for manufacturers thanks to an increase in treatment rate and rising prevalence of triple-negative breast. Increasing healthcare infrastructure in countries like India and China is expected to boost the growth of the market in the region in the coming years.
Established players of the market are: AstraZeneca PLC, Pfizer, Inc. , F. Hoffman - La Roche Ltd. , Bristol-Myers Squibb Company, Novartis AG, Mylan N.V. , Eli Lilly and Company, Celgene Corporation, Sanofi S.A., and Johnson & Johnson Services, Inc., among others.
Triple-Negative Breast Cancer Treatment Market Segmentation: By Drug Type • Doxorubicin • Cyclophosphamide • Paclitaxel • Docetaxel • Cisplatin/Carboplatin • Others
By Distribution Channel • Hospital Pharmacies • Specialty Cancer Clinics
By Region • Europe • North America • APAC • Latin America • Rest of World
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on Global Triple-Negative Breast Cancer Treatment Market by Drug Type, by Distribution Channel, by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Triple Negative Breast Cancer Treatment Market Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Triple Negative Breast Cancer Treatment Market Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Triple Negative Breast Cancer Treatment Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Triple Negative Breast Cancer Treatment Market Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Triple Negative Breast Cancer Treatment Market Market, By Drug TypeHistorical Analysis and Forecast 2020-2027 (USD Million) 7.1. Doxorubicin 7.2. Cyclophosphamide 7.3. Paclitaxel 7.4. Docetaxel 7.5. Cisplatin/Carboplatin 7.6. Others 8. Global Triple Negative Breast Cancer Treatment Market Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Hospital Pharmacies 8.2. Specialty Cancer Clinics 9. North America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2020-2027 10. Latin America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2020-2027 11. Europe Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2020-2027 12. Asia Pacific Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Saudi Arabia 13.2.2. UAE 13.2.3. South Africa 13.2.4. Egypt 13.3. Market Size (USD Million) Forecast for MEA 2020-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. AstraZeneca PLC 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Pfizer, Inc. 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. F. Hoffman - La Roche Ltd. 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. Bristol-Myers Squibb Company 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. Novartis AG 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. Mylan N.V. 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Eli Lilly and Company 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Celgene Corporation 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Sanofi S.A 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10. Johnson & Johnson Services, Inc. 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15. FutureWise SME Key Takeaway Points for Client
1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Scope
1.3.1. Years Considered for the Study
1.3.2. Market Covered
1.4. Currency
1.5. Limitations
1.6. Stakeholders
2. Research Methodology
2.1. Research Data
2.1.1. Secondary Data
2.1.1.1. Key Data from Secondary Sources
2.1.2. Primary Data
2.1.2.1. Key Data from Primary Sources
2.2. Market Size Estimation
2.3. Market Breakdown and Data Triangulation
2.4. Assumptions for the Study
3. Executive Summary
3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Global Triple Negative Breast Cancer Treatment Market Market Variables, Trends & Scope
4.1. Market Lineage Outlook
4.2. Penetration and Growth Prospect Mapping
4.3. Industry Value Chain Analysis
4.4. Cost Analysis Breakdown
4.5. Technology Overview
4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Global Triple Negative Breast Cancer Treatment Market Market Overview
5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Triple Negative Breast Cancer Treatment Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Triple Negative Breast Cancer Treatment Market Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Triple Negative Breast Cancer Treatment Market Market, By Drug TypeHistorical Analysis and Forecast 2020-2027 (USD Million)
7.1. Doxorubicin
7.2. Cyclophosphamide
7.3. Paclitaxel
7.4. Docetaxel
7.5. Cisplatin/Carboplatin
7.6. Others 8. Global Triple Negative Breast Cancer Treatment Market Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million)
8.1. Hospital Pharmacies
8.2. Specialty Cancer Clinics
9. North America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
9.1. Introduction
9.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
9.2.1. U.S.A
9.2.2. Canada
9.2.3. Mexico
9.3. Market Size (USD Million) Forecast for North America 2020-2027
10. Latin America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
10.1. Introduction
10.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
10.2.1. Brazil
10.2.2. Venezuela
10.2.3. Argentina
10.2.4. Rest of Latin America
10.3. Market Size (USD Million) Forecast for Latin America 2020-2027
11. Europe Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
11.1. Introduction
11.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
11.2.1. Germany
11.2.2. U.K
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Russia
11.2.7. Poland
11.2.8. Rest of Europe
11.3. Market Size (USD Million) Forecast for Europe 2020-2027
12. Asia Pacific Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million)
12.1. Introduction
12.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019
12.2.1. Japan
12.2.2. China
12.2.3. India
12.2.4. Australia and New Zealand
12.2.5. ASEAN
12.2.6. Rest of Asia Pacific
12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
13.1. Introduction
13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
13.2.1. Saudi Arabia
13.2.2. UAE
13.2.3. South Africa
13.2.4. Egypt
13.3. Market Size (USD Million) Forecast for MEA 2020-2027
14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
14.1. AstraZeneca PLC
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.3. SWOT Analysis
14.1.4. Financial Overview
14.1.5. Strategic Overview
14.2. Pfizer, Inc.
14.2.1. Company Overview
14.2.2. Product Portfolio
14.2.3. SWOT Analysis
14.2.4. Financial Overview
14.2.5. Strategic Overview
14.3. F. Hoffman - La Roche Ltd.
14.3.1. Company Overview
14.3.2. Product Portfolio
14.3.3. SWOT Analysis
14.3.4. Financial Overview
14.3.5. Strategic Overview
14.4. Bristol-Myers Squibb Company 14.4.1. Company Overview
14.4.2. Product Portfolio
14.4.3. SWOT Analysis
14.4.4. Financial Overview
14.4.5. Strategic Overview
14.5. Novartis AG 14.5.1. Company Overview
14.5.2. Product Portfolio
14.5.3. SWOT Analysis
14.5.4. Financial Overview
14.5.5. Strategic Overview
14.6. Mylan N.V. 14.6.1. Company Overview
14.6.2. Product Portfolio
14.6.3. SWOT Analysis
14.6.4. Financial Overview
14.6.5. Strategic Overview
14.7. Eli Lilly and Company
14.7.1. Company Overview
14.7.2. Product Portfolio
14.7.3. SWOT Analysis
14.7.4. Financial Overview
14.7.5. Strategic Overview
14.8. Celgene Corporation 14.8.1. Company Overview
14.8.2. Product Portfolio
14.8.3. SWOT Analysis
14.8.4. Financial Overview
14.8.5. Strategic Overview
14.9. Sanofi S.A 14.9.1. Company Overview
14.9.2. Product Portfolio
14.9.3. SWOT Analysis
14.9.4. Financial Overview
14.9.5. Strategic Overview 14.10. Johnson & Johnson Services, Inc. 14.10.1. Company Overview
14.10.2. Product Portfolio
14.10.3. SWOT Analysis
14.10.4. Financial Overview
14.10.5. Strategic Overview
15. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics